Article A blood based 12-miRNA signature of Alzheimer patients - GSE46579

What is it and what does it include? 

Investigators in this study applied Next-Generation Sequencing (NGS) to miRNAs from blood samples of 48 AD patients and 22 unaffected controls, yielding a total of 140 unique mature miRNAs with significantly changed expression level. Of these, 82 were higher and 58 lower abundant in samples from AD patients. We selected a panel of 12 miRNAs for a qRT-PCR analysis on a larger cohort of 202 samples comprising not only AD patients and healthy controls but also patients with other CNS illnesses, including MCI, multiple sclerosis, Parkinson disease, major depression, bipolar disorder and schizophrenia. Data obtained from this study indicate that deregulated miRNAs in blood might be used as biomarkers in the diagnosis of AD or other neurological diseases. 

How can I use this dataset to advance my research?  

This dataset is ideal if: 

  • you’re analyzing unique mature miRNAs with significantly changed expression level in patients with AD and other CNS illnesses, such as Parkinson’s, MCI, schizophrenia, depression, MS and bipolar disorder. 
  • you’re studying quantitative Real Time PCR data from whole blood samples from patients with AD and other related conditions. 

Has this dataset helped researchers understand Alzheimer’s and other dementias better? 

Of course!  

  • AD & next-generation sequencing: 

In 2013, researchers suggested that miRNA target enrichment analysis of the selected 12 miRNAs indicates an involvement of miRNAs in nervous system development, neuron projection, neuron projection development and neuron projection morphogenesis. However, they were not only able to distinguish with high diagnostic accuracies between AD patients and healthy controls, but also between AD patients and patients suffering from other neurological. Additional work will be needed to elucidate the applicability of this 12-miRNA signature as a potential diagnostic test for AD and the above-mentioned effects of the drug treatments commonly used in the treatment of the disease. Hopefully, tests of this non-invasive and relatively cheap kind will be applicable to prodromal AD cases and to MCI patients with the aim to recognize early AD to initiate treatment. July 2013 – DOI:  

Manuscripts citing this dataset 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.  


Post a question or thought about this dataset here.